Related Experiment Video
Updated: Jul 31, 2026

Optimization of the Ugi Reaction Using Parallel Synthesis and Automated Liquid Handling
Published on: November 11, 2008
Discovery and optimization of 2-aryl oxazolo-pyrimidines as adenosine kinase inhibitors using liquid phase parallel
M Bauser1, G Delapierre, M Hauswald
1BAYER AG, Bayer Health Care, Division Pharma, Medicinal Chemistry, Germany. marcus.bauser.mb@bayer-ag.de
Abstract:
Adenosine kinase inhibition is an attractive therapeutic approach for several conditions for example, neurodegeneration, seizures, ischemia, inflammation and pain. Several nucleosidic and non-nucleosidic inhibitors are available. Using a virtual screening approach, we have discovered that 2-aryl oxazolo-pyrimidines are adenosine kinase inhibitors. Subsequent high throughput derivatization enabled the optimization of this new inhibitor chemotype resulting in highly potent derivatives. A variety of analogues were produced by applying liquid phase parallel synthesis to vary the 7-amino residues as well as the 2-aryl moiety.
Related Concept Videos
Drug Discovery: Overview
Antiviral Nucleoside Inhibitors

